Efpeglenatide

Hanmi Pharm advances efpeglenatide launch to H2 2026, targeting annual sales >100 billion won. The drug, in phase 3 trials, uses gradual release to reduce GI side effects and offers cardiovascular and renal benefits. Hanmi develops Korea's first digital combination drug for personalized obesity management. Efpeglenatide will be manufactured locally, aiming to reduce reliance on foreign drugs. Hanmi's H.O.P. project includes advanced treatments like HM15275 (phase 1 in U.S.) and HM17321 (first-in-class, phase 1 in H2 2025), plus innovations like oral drugs and microneedle patches.

Hanmi Pharmaceutical reschedules efpeglenatide launch to 2H 2026, aiming for 100 billion won annual sales. The anti-obesity drug, in Phase 3 trials, targets overweight and stage 1 obese individuals, promising weight-loss effects similar to Wegovy with enhanced cardiovascular and kidney benefits. Developed with Lapscovery tech, it reduces GI side effects. A digital combination drug integrating efpeglenatide with digital therapeutics is also in development for personalized obesity management.

Hanmi Pharmaceutical's six new drugs for hypertension, dyslipidemia, diabetes, and musculoskeletal system are in phase 1-3 clinical trials. HCP1803, a low-dose triple antihypertensive, is progressing in phase 3 trials in Korea, with results presented at the ESH congress. The company launched diabetes and antithrombotic drugs, and its biologic Rolvedon generated significant sales. Hanmi is also developing a Korean-specific GLP-1 obesity drug and aims to be a global R&D-centered pharmaceutical company.